icrf 193 has been researched along with aclarubicin in 2 studies
| Studies (icrf 193) | Trials (icrf 193) | Recent Studies (post-2010) (icrf 193) | Studies (aclarubicin) | Trials (aclarubicin) | Recent Studies (post-2010) (aclarubicin) |
|---|---|---|---|---|---|
| 155 | 0 | 30 | 826 | 97 | 105 |
| Protein | Taxonomy | icrf 193 (IC50) | aclarubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 9.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mikhailov, A; Rieder, CL; Shinohara, M | 1 |
| Cortés, F; Hajji, N; Mateos, S; Pastor, N | 1 |
2 other study(ies) available for icrf 193 and aclarubicin
| Article | Year |
|---|---|
Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway.
Topics: Aclarubicin; Anaphase; Antibiotics, Antineoplastic; Antineoplastic Agents; Blotting, Western; Catalysis; Cell Line, Tumor; Chromatin; Chromosomes; Diketopiperazines; DNA Damage; Doxorubicin; Enzyme Activation; G2 Phase; HeLa Cells; Histone Deacetylase Inhibitors; Histones; Humans; Immunohistochemistry; Lasers; Microscopy, Video; Mitogen-Activated Protein Kinases; Mitosis; Osmosis; p38 Mitogen-Activated Protein Kinases; Piperazines; Spindle Apparatus; Thiobarbiturates; Time Factors; Topoisomerase II Inhibitors | 2004 |
Modulation of radiation response by inhibiting topoisomerase II catalytic activity.
Topics: Aclarubicin; Animals; Cell Line; Cell Survival; Cricetinae; Diketopiperazines; DNA Damage; DNA, Kinetoplast; Enzyme Inhibitors; Humans; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Mutation; Neoplasms; Phosphoproteins; Piperazines; Radiation Tolerance; Topoisomerase II Inhibitors | 2006 |